BRACE (UK): BCG Vaccination to reduce the impact of COVID-19 in healthcare workers
- Funded by UK Research and Innovation (UKRI)
- Total publications:0 publications
Grant number: C19-IUC-409
Grant search
Key facts
Disease
COVID-19Funder
UK Research and Innovation (UKRI)Principal Investigator
John L Campbell, Adilia WarrisResearch Location
United Kingdom, Australia…Lead Research Institution
University of ExeterResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Supportive care, processes of care and management
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Unspecified
Broad Policy Alignment
Pending
Age Group
Adults (18 and older)
Vulnerable Population
Unspecified
Occupations of Interest
Health Personnel
Abstract
From the Centre website: The BRACE trial aims to recruit 10,000 healthcare workers who work in a healthcare setting or have face-to-face contact with patients in the UK, Australia, the Netherlands, Spain, and Brazil. The results of this trial will help us find out whether, in current and future novel viral outbreaks, BCG vaccination could be used as an early intervention to protect healthcare workers and other high-risk groups. In the UK, the trial is a collaboration between Exeter Medical School's Clinical Trials Unit and the Murdoch Children's Research Institute (MCRI) in Melbourne, Australia. Professor John Campbell, Professor of General Practice and Primary Care here in University of Exeter is the principal investigator in the UK for the BRACE trial, with Professor Adilia Warris, Co-Director of the MRC Centre for Medical Mycology and Professor in Paediatric Infectious Diseases, as deputy principal investigator.